Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
APDN

APDN - Applied DNA Sciences Inc Stock Price, Fair Value and News

0.66USD-0.01 (-1.49%)Market Closed
Watchlist

Market Summary

USD0.66-0.01
Market Closed
-1.49%

APDN Stock Price

View Fullscreen

APDN RSI Chart

APDN Valuation

Market Cap

9.1M

Price/Earnings (Trailing)

-0.91

Price/Sales (Trailing)

0.68

EV/EBITDA

-0.22

Price/Free Cashflow

-1.44

APDN Price/Sales (Trailing)

APDN Profitability

Operating Margin

41.39%

EBT Margin

-74.98%

Return on Equity

-201.29%

Return on Assets

-73%

Free Cashflow Yield

-69.41%

APDN Fundamentals

APDN Revenue

Revenue (TTM)

13.4M

Rev. Growth (Yr)

-78.09%

Rev. Growth (Qtr)

-73.27%

APDN Earnings

Earnings (TTM)

-10.0M

Earnings Growth (Yr)

-438.88%

Earnings Growth (Qtr)

-15.27%

Breaking Down APDN Revenue

Last 7 days

4.9%

Last 30 days

6.7%

Last 90 days

-22.9%

Trailing 12 Months

-61.7%

How does APDN drawdown profile look like?

APDN Financial Health

Current Ratio

2.86

APDN Investor Care

Shares Dilution (1Y)

6.48%

Diluted EPS (TTM)

-0.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202317.5M16.1M13.4M0
202215.1M17.6M18.2M19.3M
20215.0M6.3M9.0M11.6M
20204.9M3.3M1.9M2.9M
20193.9M4.9M5.4M5.1M
20184.6M3.9M3.9M4.1M
20174.1M5.2M4.8M4.5M
20168.1M6.5M4.2M3.8M
20154.2M5.7M9.0M9.1M
20142.6M2.8M2.7M3.4M
20131.5M1.6M2.0M2.3M
20121.5M1.8M1.9M1.7M
2011744.3K856.6K968.8K1.2M
201000519.8K632.1K

Tracking the Latest Insider Buys and Sells of Applied DNA Sciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 23, 2023
shorrock clay
acquired
-
-
91,667
chief legal officer
Mar 23, 2023
jantzen beth
acquired
-
-
91,667
chief financial officer
Mar 23, 2023
murrah judith
acquired
-
-
99,306
cio and coo
Mar 10, 2021
anchin scott l
sold
-110,042
8.43301
-13,049
-
Mar 05, 2021
anchin scott l
acquired
56,240
4.30992
13,049
-
Jun 26, 2020
montgomery william w
bought
577,500
5.25
110,000
-
Jun 26, 2020
montgomery william w
bought
-692,000
8.65
-80,000
-
Jun 18, 2020
montgomery william w
bought
210,000
5.25
40,000
-
Jun 09, 2020
montgomery william w
bought
393,750
5.25
75,000
-
Jun 09, 2020
montgomery william w
bought
-316,560
7.914
-40,000
-

1–10 of 35

Which funds bought or sold APDN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
STATE STREET CORP
unchanged
-
-46,405
46,678
-%
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
4,869
4,869
-%
Feb 14, 2024
Royal Bank of Canada
unchanged
-
-1,000
1,000
-%
Feb 14, 2024
VANGUARD GROUP INC
unchanged
-
-310,653
323,013
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
reduced
-48.39
-127,807
44,628
-%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
sold off
-100
-15,507
-
-%
Feb 14, 2024
AWM Investment Company, Inc.
sold off
-100
-994,830
-
-%
Feb 14, 2024
SABBY MANAGEMENT, LLC
sold off
-100
-47,069,000
-
-%
Feb 14, 2024
Creative Planning
unchanged
-
-6,209
6,457
-%

1–10 of 36

Are Funds Buying or Selling APDN?

Are funds buying APDN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own APDN
No. of Funds

Unveiling Applied DNA Sciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 12, 2024
grossman bruce
9.8%
1,666,798
SC 13G
Jan 10, 2024
awm investment company, inc.
3.5%
5e+05
SC 13G/A
Feb 14, 2023
awm investment company, inc.
9.99%
720,942
SC 13G
Feb 09, 2023
grossman bruce
4.9%
658,739
SC 13G/A
Feb 14, 2022
hayward james a
6.45%
506,481
SC 13D
Feb 14, 2022
cvi investments, inc.
-
18,375
SC 13G/A
Jan 13, 2022
empery asset management, lp
0.00%
0
SC 13G/A
Jan 03, 2022
hedgehog capital llc
0.0%
0
SC 13G/A
Feb 16, 2021
hayward james a
3.82%
291,481
SC 13D/A
Jan 21, 2021
grossman bruce
8.1%
658,739
SC 13G/A

Recent SEC filings of Applied DNA Sciences Inc

View All Filings
Date Filed Form Type Document
Feb 12, 2024
SC 13G
Major Ownership Report
Feb 12, 2024
D
D
Feb 08, 2024
8-K
Current Report
Feb 08, 2024
10-Q
Quarterly Report
Feb 01, 2024
8-K
Current Report
Feb 01, 2024
424B5
Prospectus Filed
Jan 31, 2024
8-K
Current Report
Jan 26, 2024
10-K/A
Annual Report
Jan 10, 2024
SC 13G/A
Major Ownership Report
Jan 08, 2024
8-K
Current Report

Peers (Alternatives to Applied DNA Sciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
186.9B
27.6B
10.99% -3.42%
39.24
6.77
-8.71% -33.92%
47.5B
3.7B
3.78% 14.37%
56.17
12.97
8.72% 24.44%
38.7B
6.8B
3.29% -11.61%
31.19
5.66
-0.22% -1.12%
14.0B
9.3B
-8.35% -14.36%
16.44
1.52
-6.38% -9.73%
12.7B
4.1B
15.83% -0.20%
26.72
3.07
3.86% -2.39%
11.1B
2.5B
-9.16% -4.81%
-54.17
4.42
19.93% 67.26%
MID-CAP
12.1B
1.9B
36.59% 75.21%
42.82
6.42
29.17% 15.26%
8.5B
988.7M
14.98% 63.69%
-17.12
8.65
27.41% 8.51%
3.7B
918.7M
-2.97% -10.18%
316.38
4.06
45.66% 172.57%
2.7B
563.9M
-7.36% -19.90%
-5.69
4.84
25.45% 26.76%
SMALL-CAP
447.4M
297.1M
-26.16% -46.86%
-4.94
1.51
-6.74% -21.60%
85.7M
21.4M
29.35% -91.67%
-0.75
4
-8.80% -39.66%
45.6M
9.2M
-1.43% -37.11%
-2.51
4.97
16.43% 46.89%
9.1M
13.4M
6.67% -61.68%
-0.91
0.68
-26.43% -20.54%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

Applied DNA Sciences Inc News

Latest updates
Yahoo Finance43 hours ago
Quartz08 Feb 202409:40 pm
Zacks Investment Research08 Feb 202408:00 am

Applied DNA Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-73.3%779,7362,917,3414,407,6145,262,7523,559,3174,296,3716,147,2834,165,7063,039,7351,700,3202,671,5421,616,141313,989431,516552,473633,5191,672,8422,053,457778,468884,3221,195,365
Cost Of Revenue-57.5%700,7401,648,0232,600,1792,885,0693,142,5583,257,1133,658,7983,056,5681,972,3771,116,106940,568515,781154,483154,804179,582232,031320,105270,883133,141153,485250,659
Gross Profit-93.8%78,9961,269,3181,807,4352,377,683416,7591,039,2582,488,4851,109,1381,067,358584,2141,730,9741,100,360---------
Operating Expenses2.9%4,249,9964,128,4274,511,4593,596,6614,669,0653,895,9024,642,7215,815,7155,652,7204,025,9234,046,9654,073,4624,105,1623,465,5063,055,0993,012,9063,216,5823,214,2063,277,9643,926,9964,410,108
  S&GA Expenses0.6%3,311,0893,292,3043,522,7152,625,3573,756,1843,032,8773,572,6804,735,6193,528,2022,883,8123,091,2273,309,6542,783,1812,589,0422,285,5442,373,4132,259,5292,407,2232,528,9143,082,3803,571,547
  R&D Expenses12.3%938,907836,123988,744971,304912,881863,0251,070,0411,080,0961,302,7771,142,111955,738763,8081,239,720814,599703,018564,426886,669719,668651,377709,564716,692
EBITDA Margin-82.7%-0.64-0.35-0.21-0.32-0.38-0.61-0.88-1.13-1.49-2.11-2.65----------
Interest Expenses53.9%41,22426,7833,6393,6861,387-5,5402731,7003,57213,841-5,438-29,019-28,624-29,096-29,091-55,226-38,177-37,417-31,611-
Income Taxes-----------------15,000----
Earnings Before Taxes-16.1%-3,615,651-3,114,195551,176-3,844,246-664,554-1,124,796-1,759,797-4,720,911-4,507,584-3,446,715-1,517,078-4,807,062-4,125,146-3,290,112-2,950,905-2,662,741-1,218,458-1,477,911-2,686,757-3,234,320-3,475,283
EBT Margin-71.2%-0.75-0.44-0.29-0.38-0.46-0.69-0.96-1.23-1.58-2.21-2.73----------
Net Income-15.3%-3,573,243-3,099,766551,176-3,844,246-663,091-1,124,220-1,759,797-4,720,911-4,512,201-3,448,993-1,517,078-4,807,062-4,123,528-3,289,450-2,950,905-2,662,741-1,224,135-1,477,911-2,686,757-3,234,320-3,475,283
Net Income Margin-70.6%-0.75-0.44-0.29-0.38-0.46-0.69-0.96-1.23-1.58-2.21-2.73----------
Free Cashflow-92.3%-2,679,679-1,393,389160,049-2,383,106-3,501,281-1,830,981-327,417-3,806,580-5,618,495-1,752,554-4,080,317----------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-13.5%13,65215,79019,17520,29722,26511,92013,87911,40214,41717,19020,7829,67811,34113,97511,32710,8723,5652,9854,2266,1495,634
  Current Assets-33.6%8,12712,24015,38018,33219,9439,26811,1568,49911,29813,69617,4196,5409,07812,1559,9799,6382,1461,6052,7634,6004,002
    Cash Equivalents-33.5%7,15210,75612,28712,87715,2154,6826,5132,7486,55512,17313,9264,2417,78710,9258,6638,6635595071,5413,1381,660
  Inventory19.4%3302763664776021,1721,4111,3011,37042972154349744589.0083.00143310315225221
  Net PPE-28.2%8381,1681,5751,8662,2232,5572,6292,8083,0242,5772,4232,1751,278751265184226265316369420
  Goodwill----------285285285285285285285285285285285285
Liabilities2.1%8,7798,5959,20711,1399,3565,1266,2333,0103,3041,6062,1623,9555,6325,1964,0583,6484,4134,7744,9605,3834,879
  Current Liabilities-1.6%2,8452,8913,6553,3304,1854,2843,6332,9793,2721,5752,1302,9194,2662,4481,8501,5092,2461,9742,2202,7332,822
Shareholder's Equity-31.7%4,9517,2499,9689,15812,9126,7957,6478,39211,11315,58418,6205,7235,7108,7797,2697,224255,963253,482253,059766755
  Retained Earnings-1.2%-302,447-298,854-295,755-296,343-292,500-291,836-290,712-288,843-284,122-279,611-276,162-274,645-269,835-265,712-262,423-259,471-256,805-255,271-253,793-251,107-248,366
  Additional Paid-In Capital0.4%307,385306,091305,751305,493305,399298,624298,352297,228295,228295,191294,781280,369275,549274,493269,694266,699255,963253,445253,022251,838249,120
Shares Outstanding5.8%13,65912,90912,90912,90912,9098,9838,0857,4867,4866,7257,235----------
Minority Interest-42.2%-78.75-55.36-40.93-3.76-2.89-1.55-979*133*-722*-4.23-6.51-6.23-8.72-6.51-5.85-7.07-7.04----
Float---14,400---17,200---45,800---13,500---21,000--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-95.7%-2,679-1,369214-2,383-3,258-1,754-261-3,701-4,712-1,249-3,270-4,155-2,983-3,008-2,420-2,731-3,059--2,288-1,513-2,508
  Share Based Compensation0.4%34134025994.002732732731,70037.00410649571204365227205295154267490887
Cashflow From Investing-471.5%-924-161-54.3445.00-242-76.67-65.53-104-906-502-810-329-1,007-11.43-44.75--3.45--11.93-52.054.00
Cashflow From Financing-----14,03575*4,092---13,7659408525,2822,46510,8352,081-7043,0441,650

APDN Income Statement

2023-12-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenues  
Total revenues$ 891,164$ 5,262,752
Total cost of revenues660,0672,885,069
Gross profit231,0972,377,683
Operating expenses:  
Selling, general and administrative3,084,3482,625,357
Research and development935,815971,304
Total operating expenses4,020,1633,596,661
LOSS FROM OPERATIONS(3,789,066)(1,218,978)
Interest income33,3233,686
Unrealized gain (loss) on change in fair value of warrants classified as a liability2,639,000(2,637,800)
Other (expense) income, net(13,538)8,846
Loss before provision for income taxes(1,130,281)(3,844,246)
NET LOSS(1,130,281)(3,844,246)
Less: Net loss attributable to noncontrolling interest25,181874
NET LOSS attributable to Applied DNA Sciences, Inc.(1,105,100)(3,843,372)
Deemed dividend related to warrant modifications(77,757) 
NET LOSS attributable to common stockholders$ (1,182,857)$ (3,843,372)
Net loss per share attributable to common stockholders - basic$ (0.09)$ (0.30)
Net loss per share attributable to common stockholders - diluted$ (0.09)$ (0.30)
Weighted average shares outstanding - basic13,673,43312,908,520
Weighted average shares outstanding - diluted13,673,43312,908,520
Product revenues  
Revenues  
Total revenues$ 307,317$ 516,396
Total cost of revenues282,545365,378
Service revenues  
Revenues  
Total revenues247,147232,061
Clinical laboratory service revenues  
Revenues  
Total revenues336,7004,514,295
Total cost of revenues$ 377,522$ 2,519,691

APDN Balance Sheet

2023-12-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2023
Sep. 30, 2023
Current assets:  
Cash and cash equivalents$ 3,359,045$ 7,151,800
Accounts receivable, net of allowance of $75,000 at December 31, 2023 and September 30, 2023, respectively450,757255,502
Inventories377,291330,027
Prepaid expenses and other current assets402,953389,241
Total current assets4,590,0468,126,570
Property and equipment, net539,319838,270
Other assets:  
Restricted cash750,000750,000
Intangible assets2,698,9752,698,975
Operating right of use asset1,117,3171,237,762
Capitalized transaction costs217,553 
Total assets9,913,21013,651,577
Current liabilities:  
Accounts payable and accrued liabilities2,023,8762,270,388
Operating lease liability, current510,028498,598
Deferred revenue54,03576,435
Total current liabilities2,587,9392,845,421
Long term accrued liabilities31,46731,467
Deferred revenue, long term227,999194,000
Operating lease liability, long term607,288739,162
Deferred tax liability, net684,115684,115
Warrants classified as a liability1,646,0004,285,000
Total liabilities5,784,8088,779,165
Commitments and contingencies (Note G)
Applied DNA Sciences, Inc. stockholders' equity:  
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of Decenber 31, 2023 and September 30 2023, respectively
Common stock, par value $0.001 per share; 200,000,000 shares authorized as of December 31, 2023 and September 30, 2023, 13,721,820 and 13,658,520 shares issued and outstanding as of December 31, 2023 and September 30, 2023, respectively13,72213,659
Additional paid in capital307,848,612307,384,647
Accumulated deficit(303,630,004)(302,447,147)
Applied DNA Sciences, Inc. stockholders' equity4,232,3304,951,159
Noncontrolling interest(103,928)(78,747)
Total equity4,128,4024,872,412
Total liabilities and equity9,913,21013,651,577
Series A Preferred stock  
Applied DNA Sciences, Inc. stockholders' equity:  
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of Decenber 31, 2023 and September 30 2023, respectively
Series B Preferred stock  
Applied DNA Sciences, Inc. stockholders' equity:  
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of Decenber 31, 2023 and September 30 2023, respectively
APDN
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. The company operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR)-based MDx testing services for the Monkeypox virus; and MDx test kits and related supplies, as well as validates pharmacogenetics (PGx) testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, leather, pharmaceuticals, nutraceuticals, and other products; SigNify IF portable DNA readers and SigNify consumable reagent test kits, which offers a front-line solution for supply chain integrity backed with forensic-level molecular tag authentication; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
 CEO
 WEBSITEwww.adnas.com
 EMPLOYEES61

Applied DNA Sciences Inc Frequently Asked Questions


What is the ticker symbol for Applied DNA Sciences Inc? What does APDN stand for in stocks?

APDN is the stock ticker symbol of Applied DNA Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Applied DNA Sciences Inc (APDN)?

As of Thu Feb 22 2024, market cap of Applied DNA Sciences Inc is 9.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APDN stock?

You can check APDN's fair value in chart for subscribers.

What is the fair value of APDN stock?

You can check APDN's fair value in chart for subscribers. The fair value of Applied DNA Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Applied DNA Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APDN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Applied DNA Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether APDN is over valued or under valued. Whether Applied DNA Sciences Inc is cheap or expensive depends on the assumptions which impact Applied DNA Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APDN.

What is Applied DNA Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, APDN's PE ratio (Price to Earnings) is -0.91 and Price to Sales (PS) ratio is 0.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APDN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Applied DNA Sciences Inc's stock?

In the past 10 years, Applied DNA Sciences Inc has provided -0.466 (multiply by 100 for percentage) rate of return.